Teleflex Adds Minimally Invasive BPH System With NeoTract Buy

Teleflex is forking out over $1bn for privately held NeoTract. The latter has seen its revenues grow rapidly due to market enthusiasm for its UroLift system for treating lower urinary tract symptoms related to benign prostatic hyperplasia.

More from Surgery

More from Device Area